Forging the company as the biggest pharmaceutical e-com platform in Taiwan• Direct reports: 7; headcount managed in corporate level: 50;• First pharmaceutical e-com platform with e-payment in Taiwan with more than 4,000 drugstores members, representing 2/3+ market share;• A constant sales growth rate of 30%+ YoY;• Completed 3 private offerings to enhance the soundness of capital;• Develop location based service strategically allied with LINE;• Exclusive agency from Pfizer and Novartis for certain products;

The largest project management solution provider for IT and construction industries.Develop company strategy and execution• Successfully turning around operation and profits post• Direct reports: 5; headcount managed in corporate level: 40.

• Direct reports: 7; headcount managed in corporate level: 80;• Oversees finance, accounting, HR, administration and IT departments;• Corporate Strategy Committee member: set out and deploy a 5-years financial plans aligning the corporate development, optimized capital structure and dividends policies executions, resources planning for corporate organic and non-organic growth needs;• Being the company’s spokesman communicating with institutional investors;• Mandates taker for communication with authorities including SEC, OTC;• Ensure the company’s financial status in line with corporate develop strategy;• Primary fund raising: public offering amounted NT$ 6Billion;• Secondary fund raising: issued Euro-Convertible Bonds totally US$135mm;• Financing: completed Loan Syndication in NT$ 1.8Billion;• Responsible for strategic investment evaluation and executions, including business models evaluations, industry studies, due diligence, management interviews, site visits, operation projections, legal and compliance, alignment with corporate development strategy, optimal investment structure and execution methods (i.e. cash and stocks combinations, phases execution, exits mechanism); • Short term investment: identify investment targets, including listed stocks, assets swap instruments, re-purchase bonds, options and futures on hedging base, evaluation, duration matching and executions. A 18% IR recorded.• Review company process to seek efficiency to rationalize cost and expenses;